Last updated: April 25, 2026
Qsymia (phentermine hydrochloride and topiramate extended-release) is marketed in the US by VIVUS, Inc. (formerly under Vivus branding). The product’s supply chain is built through (1) active pharmaceutical ingredient (API) and intermediate sourcing, (2) finished-dose and packaging manufacturing, and (3) distribution by authorized wholesalers and pharmacy benefit channels. Public, reliable supplier identification for each manufacturing step is limited because Qsymia’s specific contract manufacturers and API sites are not consistently disclosed in open sources at the level of “named suppliers” for the full global supply chain.
Who is the named commercial supplier?
VIVUS, Inc. is the marketing authorization holder / branded product owner in the US for Qsymia.
| Role |
Entity |
Evidence |
| US brand owner / commercial sponsor |
VIVUS, Inc. |
Qsymia US product labeling lists VIVUS as the manufacturer/marketer information associated with the product (labeling records) |
What companies manufacture and supply the dosage form?
Open-labeling records do not consistently name the full set of contract manufacturing organizations (CMOs) and packaging sites for Qsymia at a supplier-by-supplier granularity. Public label text typically provides the manufacturer name for the commercial product and sometimes the packaging site, but it varies by revision date and by jurisdiction.
What is consistently available in public sources is that Qsymia is produced as a fixed-dose extended-release combination (phentermine + topiramate ER). That implies that supply must include ER formulation capabilities and multi-component manufacturing (phentermine HCl and topiramate ER layer/control strategy).
| Product characteristic driving supply needs |
Qsymia requirement |
| ER dosage form |
ER formulation and controlled-release manufacturing capability |
| Combination tablet |
Multi-API blend and fixed-dose compression process |
| Controlled quality release |
Analytical and stability testing for ER release profile |
Is Qsymia tied to a specific API supplier in public sources?
Public patent and regulatory records generally identify drug substance and process inventors, but they do not reliably publish the commercial API supplier list used for every market batch. API sourcing is also commonly switched across sites over the life of a product based on cost, capacity, and regulatory inspections.
What can be stated from public materials is that Qsymia’s APIs are phentermine hydrochloride and topiramate (for ER), and the supply chain must cover GMP synthesis and ER-ready drug substance strategy.
What about wholesalers and distribution?
In the US, Qsymia is distributed through standard pharmaceutical distribution channels (authorized wholesalers, chain pharmacies, specialty pharmacy networks where applicable). Wholesaler identities are not fixed as “suppliers” in the patent-analyst sense; they vary by contract, region, and customer.
Practical supplier mapping for due diligence
For investment and R&D diligence, Qsymia supplier discovery is typically done via three pathways:
- US FDA labeling and product database records (manufacturer/labeler and sometimes site information by revision)
- Product-specific packaging/manufacturer listings in regulatory submissions where available
- Wholesale acquisition cost (WAC) distribution channels and authorized distributor lists where public
However, since open sources do not provide a stable, complete list of all upstream API and CMO suppliers for Qsymia, the only defensible “named supplier” you can treat as fixed from public records is the US brand owner/labeler: VIVUS, Inc.
Key Takeaways
- VIVUS, Inc. is the fixed commercial sponsor/labeler for Qsymia in the US.
- Public records do not consistently disclose a complete supplier roster for Qsymia’s API sources and all contract manufacturing/packaging sites.
- Qsymia supply requires ER formulation and fixed-dose combination manufacturing, so any supplier roster you build must be screened for ER capability and multi-API compression readiness.
- For named CMO/API supplier identification, you typically must rely on labeling revision records and product-registration documents at the batch/site level, which are not fully standardized in public datasets.
FAQs
-
Who owns and markets Qsymia in the US?
VIVUS, Inc. is the US product owner/labeler associated with Qsymia.
-
Is the full list of Qsymia API suppliers publicly available?
Not consistently. Open sources typically identify the drug and regulatory context but not the complete set of commercial API suppliers used over time.
-
What manufacturing capability must Qsymia suppliers have?
Suppliers must support extended-release (ER) formulation and fixed-dose combination manufacturing for phentermine HCl plus topiramate ER.
-
Do wholesaler identities matter for “suppliers” of Qsymia?
They matter for distribution contracts, but wholesalers are not a fixed set of upstream “suppliers” and can vary by market and customer.
-
Where do named manufacturer details usually appear for Qsymia?
In US product labeling/manufacturer information within regulatory and label revision records, which can change by site and over time.
References
[1] US Food and Drug Administration. Qsymia (phentermine hydrochloride and topiramate extended-release) prescribing information / labeling records. FDA label database (accessed 2026).
